Ovarian Cancer News and Research RSS Feed - Ovarian Cancer News and Research Twitter

Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
Moffitt researcher uncovers new approach to treat cancer

Moffitt researcher uncovers new approach to treat cancer

The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs. [More]
Dietary flavonoids decrease risk of developing epithelial ovarian cancer

Dietary flavonoids decrease risk of developing epithelial ovarian cancer

Tea and citrus fruits and juices are associated with a lower risk of developing ovarian cancer, according to new research from the University of East Anglia. [More]
UT Southwestern receives CPRIT grant to expand genetic screening services in North Texas

UT Southwestern receives CPRIT grant to expand genetic screening services in North Texas

Genetic screening services for rural and underserved populations will expand from six to 22 counties in North Texas under a $1.5 million grant from the Cancer Prevention and Research Institute of Texas to UT Southwestern Medical Center. [More]
Despite rise in use of hospice care, hospital-based services increase for ovarian cancer patients

Despite rise in use of hospice care, hospital-based services increase for ovarian cancer patients

There have been widespread efforts to improve the quality of life of terminally ill patients. As more patients choose to spend their final days and weeks in hospice care rather than a hospital, the hope is the use of intensive and costly hospital services would decline. [More]
Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers at the University of Connecticut have found a new way to identify protein mutations in cancer cells. The novel method is being used to develop personalized vaccines to treat patients with ovarian cancer. [More]
Half-day educational program can help educate women on side effects of cancer prevention surgery

Half-day educational program can help educate women on side effects of cancer prevention surgery

More women are having ovary-removing surgery as a cancer prevention measure, but many are often unaware of sexual or psychological side effects of the procedure. A new study by researchers at Dana-Farber Cancer Institute shows a half-day educational program can help successfully deal with these issues by educating women on how to address them. [More]
Researchers develop ADNEX test to help doctors diagnose ovarian cancer, choose best treatment

Researchers develop ADNEX test to help doctors diagnose ovarian cancer, choose best treatment

Researchers have devised a new test to help doctors diagnose ovarian tumours and choose the most appropriate treatment. [More]
Penn Medicine announces recipients of new Basser External Research Grant Program

Penn Medicine announces recipients of new Basser External Research Grant Program

The University of Pennsylvania's Basser Research Center for BRCA has announced $6.9 million to research teams both at Penn and at five other institutions across the United States, aimed at advancing the care of patients living with BRCA1 and BRCA2 mutations through multi-disciplinary collaboration. [More]
Conventional laparoscopy less complicated than robot-assisted surgery for benign gynecologic conditions

Conventional laparoscopy less complicated than robot-assisted surgery for benign gynecologic conditions

For benign gynecologic conditions, robot-assisted surgery involves more complications during surgery and may be significantly more expensive than conventional laparoscopic surgery, according to a study by researchers at Columbia University Medical Center. [More]
BRCA mutations carry risks for salivary gland cancer, breast cancer

BRCA mutations carry risks for salivary gland cancer, breast cancer

The risk of developing cancer in a salivary gland might be higher in people with mutations in either of two genes associated with breast and ovarian cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. [More]
Lung cancer can be detected much earlier using lab-on-a-chip technology

Lung cancer can be detected much earlier using lab-on-a-chip technology

Scientists have been laboring to detect cancer and a host of other diseases in people using promising new biomarkers called "exosomes." Indeed, Popular Science magazine named exosome-based cancer diagnostics one of the 20 breakthroughs that will shape the world this year. Exosomes could lead to less invasive, earlier detection of cancer, and sharply boost patients' odds of survival. [More]
Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

Myriad Genetics, Inc. today announced that its Tumor BRACAnalysis CDx- companion diagnostic test significantly improved the detection of cancer-causing BRCA1/2 mutations by 44 percent in women with ovarian cancer. Data from this new study were presented at the 2014 European Society for Medical Oncology annual meeting in Madrid, Spain. [More]
FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer. [More]
Lya Segall Ovarian Cancer Institute at Mercy opens in Maryland

Lya Segall Ovarian Cancer Institute at Mercy opens in Maryland

Mercy Medical Center has announced the opening of The Lya Segall Ovarian Cancer Institute at Mercy, the first center in Maryland specifically designed and dedicated solely for the diagnosis and treatment of ovarian cancer. [More]
Study identifies potential way to improve treatment for chemo-resistant ovarian cancer

Study identifies potential way to improve treatment for chemo-resistant ovarian cancer

Ovarian cancer is the most deadly gynecological cancer, claiming the lives of more than 50% of women who are diagnosed with the disease. [More]
ImmunoCellular signs licensing agreement with Caltech to develop antigen-specific T-cell technology

ImmunoCellular signs licensing agreement with Caltech to develop antigen-specific T-cell technology

ImmunoCellular Therapeutics, Ltd. announced today that it has established a licensing agreement with the California Institute of Technology for exclusive rights to novel technology for the development of certain antigen specific T-cell immunotherapies for the treatment of cancer. [More]
Researchers develop protein therapy that may stop cancer growth

Researchers develop protein therapy that may stop cancer growth

A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body. [More]
Genetic testing for breast cancer doubled due to 'Angelina Jolie effect'

Genetic testing for breast cancer doubled due to 'Angelina Jolie effect'

In May 2013 Angelina Jolie, who was then Hollywood's highest-paid actress, underwent a double mastectomy after testing positive for a BRCA1 gene mutation that significantly increases the risk of developing breast cancer. A recent study, published by Breast Cancer Research has found that, public knowledge of her decision doubled NHS referrals for genetic testing for breast cancer risk. [More]
Curie-Cancer, Inventiva launch Epicure project that aims to develop epigenetic targets for cancer

Curie-Cancer, Inventiva launch Epicure project that aims to develop epigenetic targets for cancer

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and Inventiva, a drug discovery company that focuses on therapeutic approaches involving transcription factors and epigenetic targets, today announce the launch of the Epicure project, which has just received financial backing from France’s national research agency, the ANR [Agence Nationale pour la Recherche]. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]